Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate-Reference-Cited by-同舟云学术

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

Published:2008-08-01 Issue:8 Volume:67 Page:1096-1103
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Annals of the Rheumatic Diseases

Author:

Schiff M,Keiserman M,Codding C,Songcharoen S,Berman A,Nayiager S,Saldate C,Li T,Aranda R,Becker J-C,Lin C,Cornet P L N,Dougados M

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Cited by 444 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CTLA4-Ig exerts preferable effect for both bone erosion and bone microarchitecture in rheumatoid arthritis: Results of a prospective, non-randomized two-group study using HR-pQCT;2024-08-09

2. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis;Arthritis Research & Therapy;2024-06-06

3. Non-TNF biologics and their biosimilars in rheumatoid arthritis;Expert Opinion on Biological Therapy;2024-05-22

4. Factors contributing to the improvement in Japanese Health Assessment Questionnaire after 3 years of treatment with abatacept in biologic-naïve rheumatoid arthritis patients: Interim results of a long-term, observational, multicentre study in Japan (ORIGAMI);Modern Rheumatology;2024-05-10

5. Disease-modifying antirheumatic drug selection in Japanese patients with rheumatoid arthritis treated with biologics or JAK inhibitors without methotrexate: A retrospective hospital-based administrative claims database study;Modern Rheumatology;2024-03-07